Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Abliva AB
ABLICurrent price
0.14 SEK
-0.0038 SEK (-2.71%)
Last closed
0.14 SEK
Company
abliva.com
ISIN
SE0002575340
Sector
Healthcare
Industry
Biotechnology
Exchange
Stockholm Exchange
Capitalization
245 620 891 SEK
Yield for 12 month
-37.52 %
1Y
3Y
5Y
10Y
15Y
ABLI
Abliva AB (publ) discovers and develops medicines for the treatment of mitochondrial disease in Sweden. The company is developing KL1333 that is in Phase 2 clinical trial to treat chronic fatigue and myopathy in genetically confirmed adult patients with primary mitochondrial disease; and NV354, which has completed preclinical development for the treatment of mitochondrial disease with neurologic complications. It has a licensing and collaboration agreement with Owl Therapeutics for NeuroSTAT for the treatment of traumatic brain injury; and Yungjin Pharm on the clinical development of the KL1333, as well as Isomerase, Children's Hospital of Philadelphia, Newcastle University and University College London, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden. Address: Medicon Village, Lund, Sweden, 223 81
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
10.98 SEKP/E ratio
–Dividend Yield
–Current Year
+138 809 SEK
Last Year
+31 404 SEK
Current Quarter
–
Last Quarter
–
Current Year
-36 132 882 SEK
Last Year
-86 023 681 SEK
Current Quarter
-496 460 SEK
Last Quarter
-491 386 SEK
Key Figures ABLI
1 year
3 years
5 years
10 years
EBITDA
-93 143 274 SEK
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-53.08 %
PEG Ratio
–
Return On Equity TTM
-104.31 %
Wall Street Target Price
10.98 SEK
Revenue TTM
138 805 SEK
Book Value
0.055 SEK
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-100 %
Dividend Yield
–
Gross Profit TTM
-67 427 858 SEK
Earnings per share
-0.091 SEK
Diluted Eps TTM
-0.091 SEK
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics ABLI
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ABLI
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation ABLI
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
1439.2294
Price Sales TTM
1769.5382
Enterprise Value EBITDA
-2.1686
Price Book MRQ
3.5958
Financials ABLI
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators ABLI
For 52 weeks
0.12 SEK
0.34 SEK
50 Day MA
0.17 SEK
Shares Short Prior Month
–
200 Day MA
0.18 SEK
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart